This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Vermont
Licensed Vermont practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Vermont buyers need their own professional license and NPI; the wholesale drug outlet license is the supplier’s obligation, not the purchaser’s.
Vermont deserves a closer read than its size suggests. Act 61 of 2021 is a notice and disclosure law for unapproved stem cell products, and its definition is the broadest in the country: it expressly includes intracellular or extracellular components or vesicles when a product is offered on a claimed attribute of stem cells. A Vermont practice administering such products owes patients a written notice, a posted notice, and a signed disclosure form, and the same notice belongs in its advertising.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Vermont? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | S.22 (Act 61) (2021) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Vermont
ExaVeyra ships to licensed practices in all 50 states, Vermont included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Vermont professional license in good standing, verifiable through the Board of Medical Practice or the Office of Professional Regulation license lookup.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Vermont resale certificate through the Department of Taxes if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Vermont licenses the prescription drug supply chain through the Board of Pharmacy, which sits inside the Secretary of State’s Office of Professional Regulation. Under 26 V.S.A. § 2067, no person may engage in wholesale distribution or manufacturing in Vermont without a license under the pharmacy subchapter, and the Board may require a separate license for each facility under common ownership. Out-of-state wholesalers and manufacturers shipping into Vermont license as nonresident drug outlets on the Board’s wholesale drug outlet applications. The license sits with the distributor, not with the purchasing practice.
26 V.S.A. § 2067; Vermont Board of Pharmacy Administrative Rules · Vermont Board of Pharmacy, Office of Professional Regulation, Secretary of State
Vermont regenerative-medicine law
Vermont enacted S.22 (Act 61), codified at 18 V.S.A. ch. 90, §§ 4501, 4502, effective 1 July 2021.
Health care practitioners licensed by the Vermont Board of Medical Practice or by the Office of Professional Regulation who administer stem cell or stem cell-related products not approved by the FDA. The duties are notice, display, advertising, and signed disclosure rather than a prohibition: the statute does not ban administration, it makes silence about FDA status a disciplinary matter, since failure to comply constitutes unprofessional conduct under the Board of Medical Practice and Office of Professional Regulation statutes. Practitioners holding an IND or IDE for the use, those administering under contract with institutions certified by listed national bodies, and those with an FDA determination that approval is not required for their specific use are exempt.
- Written notice to the patient before the first administration
- Notice posted at the entrance and in areas visible to patients
- Signed disclosure form before each administration, retained in the record
- The notice repeated in any advertising for unapproved products
- Exemptions for IND or IDE holders and certain accredited institutional settings
“"Stem cell and stem cell-related products" means any articles that contain or consist, or purport to contain or consist, of one or more of the following, when intended for implantation, transplantation, infusion, or transfer into a human recipient and when intended for use in the diagnosis, cure, mitigation, treatment, or prevention of any disease or condition based on or in connection with a proven or purported attribute of stem cells: (i) human cells, including cells from tissues such as bone marrow; adipose tissue; amniotic membrane; umbilical cord blood, when not autologous or in a first- or second-degree relative; placenta; and other tissue or cell sources; (ii) intracellular or extracellular components or vesicles; or (iii) amniotic fluid.”
How this applies to exosomes
Vermont is the state where the usual line, that a stem cell statute written around cells and tissues does not reach acellular vesicles, must not be written. Act 61 never uses the word exosome, but its definition of stem cell and stem cell-related products expressly includes intracellular or extracellular components or vesicles when an article is offered on a proven or purported attribute of stem cells. Exosomes are extracellular vesicles, so a Vermont practice administering exosome products marketed on stem cell attributes should assume the notice, advertising, and signed disclosure duties apply, and should put that question to its own counsel rather than rely on the product name. A state disclosure duty is not an FDA approval, and compliance with it establishes nothing about a product’s federal status: no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Vermont practice
Vermont runs on two models. An experienced APRN-led practice operates on its own authority once the 1613 transition is complete, with no standing physician agreement. A physician-led practice delegates conventionally under Board of Medical Practice oversight. The layer peculiar to Vermont sits elsewhere: whoever evaluates and administers, the Act 61 notice and disclosure duties attach to the practitioner administering any unapproved stem cell or stem cell-related product, and the definition of those products is broad enough to require a counsel review for vesicle-based offerings.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Vermont Board of Medical Practice under the Medical Practice Act perform medical acts within their scope and are the source of delegation in a physician-led practice. Cosmetic injectables and energy-based device treatments are the practice of medicine in Vermont, delegable within the usual supervision rules. |
| NP / APRN | Vermont advanced practice registered nurses are licensed by the Board of Nursing within the Office of Professional Regulation and are authorized to perform acts of medical diagnosis and to prescribe under 26 V.S.A. § 1572. An APRN with fewer than 24 months and 2,400 hours of licensed active advanced practice in an initial role and population focus practices under a formal collaborative provider agreement per 26 V.S.A. § 1613; once those thresholds are met the APRN notifies the Board and may practice solo. |
| PA | Physician assistants are licensed through the Board of Medical Practice and practice within a scope agreed with participating physicians under the Board’s framework. |
| RN | Registered nurses practice under the Nurse Practice Act in 26 V.S.A. chapter 28 and carry out treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or set the treatment plan. |
Good faith examination
Vermont expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an advanced practice registered nurse has completed the transition to independent practice, that provider can be the APRN. The expectations sit in board standards rather than a named good faith examination statute, so confirm current requirements with the Board of Medical Practice and the Board of Nursing.
Ownership and clinic licensing
Vermont has no general corporate practice of medicine prohibition of the Texas or New York kind, and non-physician entities have long been able to employ physicians. The legislature moved in 2026, but narrowly: Act 133 (H.583), an act relating to clinical decision making, added 18 V.S.A. §§ 9771 through 9774, which limit control over clinical decision making by private equity groups and hedge funds and require reporting of ownership and control of certain health care entities. That is a targeted control statute, not an ownership ban, so entity structure in Vermont remains workable for management arrangements that leave clinical judgment with licensees. Review any investor-backed structure against Act 133 with Vermont counsel.
Cold chain into Vermont
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Vermont order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Burlington | Chittenden | Largest Vermont market, with the state’s main medical and aesthetic concentration. |
| South Burlington | Chittenden | Served alongside Burlington on the same lane. |
| Stowe | Lamoille | Resort market with wellness and recovery-oriented practices. |
| Montpelier | Washington | Capital market in central Vermont. |
| Rutland | Rutland | Southwestern regional center. |
| Brattleboro | Windham | Southeastern market serving the Connecticut River valley. |
- Vermont orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in Vermont
Vermont licensing and verification
Vermont Board of Medical Practice
Sits within the Department of Health; licenses physicians and physician assistants.
Vermont Board of Nursing (Office of Professional Regulation)
Licenses APRNs, who practice independently after the 24-month transition.
Vermont Board of Pharmacy (Office of Professional Regulation)
Licenses the wholesale drug outlets that ship prescription drugs into Vermont.
Vermont Department of Taxes
Sales tax registration and resale certificates.
Vermont sourcing questions
- Does Vermont have a stem cell law?
- Yes, a disclosure law. Act 61 of 2021, codified at 18 V.S.A. chapter 90, does not ban unapproved stem cell products; it requires the administering practitioner to give a written notice before first administration, post the notice at the entrance and in visible areas, include it in advertising, and obtain a signed disclosure form before each administration, keeping a copy in the record. Noncompliance is unprofessional conduct. The duty is honesty about FDA status, not a prohibition.
- Does Vermont’s Act 61 cover exosomes?
- The statute never uses the word exosome, but its definition of stem cell and stem cell-related products expressly includes intracellular or extracellular components or vesicles when a product is offered on a proven or purported attribute of stem cells. Exosomes are extracellular vesicles, so a Vermont practice administering exosome products marketed that way should assume the notice and disclosure duties apply and confirm the question with its own counsel. No exosome product is FDA approved for administration to humans.
- Can a nurse practitioner run a practice in Vermont without a physician?
- Yes, within APRN scope, once the transition is complete. Under 26 V.S.A. § 1613 an APRN with fewer than 24 months and 2,400 hours of licensed active advanced practice works under a collaborative provider agreement and may not practice solo. Once the thresholds are met and the Board is notified, the APRN evaluates, diagnoses, and prescribes independently.
- Does Vermont enforce the corporate practice of medicine?
- Not as a general ownership ban. Vermont has no statute restricting medical practice ownership to physicians. In 2026, Act 133 added targeted rules instead: limits on control over clinical decision making by private equity groups and hedge funds, and ownership reporting for certain health care entities, at 18 V.S.A. §§ 9771 to 9774. Investor-backed structures should be reviewed against Act 133 with Vermont counsel.
- Does my Vermont clinic need a wholesale drug outlet license to buy exosomes?
- No. The wholesale drug outlet license under 26 V.S.A. § 2067 is held by the distributor or manufacturer shipping into Vermont, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial. In Vermont, that federal status is exactly what the Act 61 notice and disclosure forms exist to put in front of the patient.
- How long does cold-chain shipping take to Vermont?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- 18 V.S.A. chapter 90, stem cell products (Act 61 as codified) (accessed 16 October 2026)
- Act 61 (2021) summary, Office of Legislative Counsel (accessed 16 October 2026)
- 26 V.S.A. § 2067, wholesale distributors and manufacturers, licensure required (accessed 16 October 2026)
- 26 V.S.A. § 1613, APRN transition to practice (accessed 16 October 2026)
- Vermont Board of Pharmacy, wholesale drug outlet application instructions (accessed 16 October 2026)
- H.583 (Act 133, 2026), clinical decision making, bill status (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark definition and characterization standard for extracellular vesicles, the scientific vocabulary behind this page’s reading of Vermont’s statutory phrase extracellular components or vesicles.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from consensus guidelines and the COA, not from the state disclosure statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval, which is the very fact Vermont’s disclosure forms put before the patient.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.